Remix Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 56

Employees

  • Latest Deal Type
  • PIPE
  • (In Progress)

  • Latest Deal Amount
  • $100M

  • Investors
  • 13

Remix Therapeutics General Information

Description

ReMix Therapeutics Inc is a clinical-stage biotechnology company focused on developing small molecule therapeutics to modulate ribonucleic acid (RNA) processing and address the underlying drivers of disease. Its flagship program, REM-422, is an investigational oral mRNA degrader targeting the MYB oncogenic transcription factor, which is being developed for the treatment of adenoid cystic carcinoma (ACC), acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and other cancers.

Contact Information

Website
www.remixtx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 100 Forge Road
  • Suite 400
  • Watertown, MA 02472
  • United States
+1 (781)
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 100 Forge Road
  • Suite 400
  • Watertown, MA 02472
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Remix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. PIPE 24-Jun-2026 $100M In Progress Clinical Trials - General
4. Reverse Merger 24-Jun-2026 Announced Clinical Trials - General
3. Later Stage VC 03-Jan-2024 Completed Clinical Trials - General
2. Early Stage VC (Series B) 24-Mar-2022 $70M $153M Completed Clinical Trials - General
1. Early Stage VC (Series A) 08-Dec-2020 $83M $83M Completed Clinical Trials - General
To view Remix Therapeutics’s complete valuation and funding history, request access »

Remix Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed 17,964,705 $0.000100 8% $0.95 $0.95 1x $0.95 17.05%
To view Remix Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Remix Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ReMix Therapeutics Inc is a clinical-stage biotechnology company focused on developing small molecule therapeutics to mo
Drug Discovery
Watertown, MA
56 As of 2026

Waltham, MA
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Remix Therapeutics Competitors (4)

One of Remix Therapeutics’s 4 competitors is Skyhawk Therapeutics, a Venture Capital-Backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Skyhawk Therapeutics Venture Capital-Backed Waltham, MA
Ribometrix Venture Capital-Backed Durham, NC
Arrakis Therapeutics Venture Capital-Backed Waltham, MA
PTC Therapeutics Formerly VC-backed Warren, NJ
To view Remix Therapeutics’s complete competitors history, request access »

Remix Therapeutics Patents

Remix Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026227027-A1 Methods for identifying and treating cancer Pending 25-Apr-2025
WO-2026128832-A2 Compounds and related methods useful for degradation of cyclin k and inhibition of cyclin dependent kinases Pending 12-Dec-2024
WO-2026128832-A3 Compounds and related methods useful for degradation of cyclin k and inhibition of cyclin dependent kinases Pending 12-Dec-2024
WO-2025245472-A1 Compounds and related methods useful for degradation of cyclin k and inhibition of cyclin dependent kinases Pending 24-May-2024
WO-2025227032-A1 Methods for degradation of cyclin k and inhibition of cyclin dependent kinases Pending 26-Apr-2024 C07D403/10
To view Remix Therapeutics’s complete patent history, request access »

Remix Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Remix Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Willett Advisors Family Office Minority
WTT Investment Family Office Minority
Surveyor Capital Hedge Fund Minority
Alexandria Venture Investments Venture Capital Minority
ARCH Venture Partners Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Remix Therapeutics Acquisitions (1)

Remix Therapeutics’s most recent deal was a Merger/Acquisition with Passage Bio. The deal was made on 24-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Passage Bio 24-Jun-2026 Merger/Acquisition Drug Discovery
To view Remix Therapeutics’s complete acquisitions history, request access »

Remix Therapeutics FAQs

  • When was Remix Therapeutics founded?

    Remix Therapeutics was founded in 2019.

  • Where is Remix Therapeutics headquartered?

    Remix Therapeutics is headquartered in Watertown, MA.

  • What is the size of Remix Therapeutics?

    Remix Therapeutics has 56 total employees.

  • What industry is Remix Therapeutics in?

    Remix Therapeutics’s primary industry is Drug Discovery.

  • Is Remix Therapeutics a private or public company?

    Remix Therapeutics is a Private company.

  • What is Remix Therapeutics’s current revenue?

    The current revenue for Remix Therapeutics is .

  • How much funding has Remix Therapeutics raised over time?

    Remix Therapeutics has raised $213M.

  • Who are Remix Therapeutics’s investors?

    Willett Advisors, WTT Investment, Surveyor Capital, Alexandria Venture Investments, and ARCH Venture Partners are 5 of 13 investors who have invested in Remix Therapeutics.

  • Who are Remix Therapeutics’s competitors?

    Skyhawk Therapeutics, Ribometrix, Arrakis Therapeutics, and PTC Therapeutics are competitors of Remix Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process